136 related articles for article (PubMed ID: 11769963)
1. Cytokine deregulation in cancer.
Kurzrock R
Biomed Pharmacother; 2001 Nov; 55(9-10):543-7. PubMed ID: 11769963
[TBL] [Abstract][Full Text] [Related]
2. Cytokine deregulation in hematological malignancies: clinical and biological implications.
Kurzrock R
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2581-4. PubMed ID: 9815659
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
5. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in malignant lymphomas: review and prospective evaluation.
Hsu SM; Waldron JW; Hsu PL; Hough AJ
Hum Pathol; 1993 Oct; 24(10):1040-57. PubMed ID: 8406414
[TBL] [Abstract][Full Text] [Related]
7. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
[TBL] [Abstract][Full Text] [Related]
8. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.
Fischer M; Bijman M; Molin D; Cormont F; Uyttenhove C; van Snick J; Sundström C; Enblad G; Nilsson G
Leukemia; 2003 Dec; 17(12):2513-6. PubMed ID: 14562126
[TBL] [Abstract][Full Text] [Related]
9. [Cytokines and malignant lymphomas].
Feller AC; Merz H
Verh Dtsch Ges Pathol; 1992; 76():70-8. PubMed ID: 1283279
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
[TBL] [Abstract][Full Text] [Related]
11. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
Fayad L; Cabanillas F; Talpaz M; McLaughlin P; Kurzrock R
Leuk Lymphoma; 1998 Aug; 30(5-6):563-71. PubMed ID: 9711918
[TBL] [Abstract][Full Text] [Related]
12. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
[TBL] [Abstract][Full Text] [Related]
13. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.
Merz H; Fliedner A; Orscheschek K; Binder T; Sebald W; Müller-Hermelink HK; Feller AC
Am J Pathol; 1991 Nov; 139(5):1173-80. PubMed ID: 1951632
[TBL] [Abstract][Full Text] [Related]
14. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
16. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
17. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.
Rutkowski P; Kaminska J; Kowalska M; Ruka W; Steffen J
Int J Cancer; 2002 Aug; 100(4):463-71. PubMed ID: 12115531
[TBL] [Abstract][Full Text] [Related]
18. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Ebrahimi B; Tucker SL; Li D; Abbruzzese JL; Kurzrock R
Cancer; 2004 Dec; 101(12):2727-36. PubMed ID: 15526319
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.
Seymour JF; Talpaz M; Cabanillas F; Wetzler M; Kurzrock R
J Clin Oncol; 1995 Mar; 13(3):575-82. PubMed ID: 7884418
[TBL] [Abstract][Full Text] [Related]
20. Biologic and molecular characterization of non-Hodgkin's lymphoma.
Gaidano G; Dalla-Favera R
Curr Opin Oncol; 1993 Sep; 5(5):776-84. PubMed ID: 8218489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
